Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its StockReward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit\n\n\n\n TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce a public whistleblower policy with a potential cash reward of up to USD $7 million to any individual or entity who can provide definitive and verifiable proof that they were asked, instructed, hired, or otherwise induced to manipulate the Company’s stock. The following individuals or entities are not eligible to receive rewards: 1) current directors, officers, or employees of the Company; 2) members of law enforcement, regulatory agencies, or government officials acting in an official capacity; 3) individuals who obtained information unlawfully or in violation of legal or professional duties; and 4) individuals who knowingly submit false, misleading, or fabricated information. The Company will not use the information until the information provider gives consent to the Company to use the information. Those with information can submit directly to\n \n [email protected]\n \n or call 1-833-571-1811.\n \n\n\n When formulating this whistleblower reward and policy, Quantum BioPharma received legal opinions and comprehensive advice from multiple law firms/legal counsel, as well as the approval of its audit committee and its board of directors.\n \n\n The cash reward of up to USD $7 million will be paid if that information tangibly and significantly contributes evidence which leads to a final, non‑appealable judgment in favour of the Company, or a binding settlement. This information includes, but is not limited to, evidence of tactics used such as: 1) illegal “spoofing” trades or, at another’s behest; 2) the deliberate spreading of fals...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B